| Bioactivity | Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1[1]. |
| Target | TNFR |
| Invitro | Lenercept (TNFR-IgG) 在放线菌素 D (HY-17559) 处理的小鼠 L-M 细胞中阻断 TNF-α 和 TNF-β 的细胞溶解作用，IC50 分别为 0.5 μg/mL 和 1.5 μg/mL[2]。 |
| In Vivo | Lenercept (Ro 45-2081) 抑制 Sephadex 诱导的大鼠肺损伤[1]。Lenercept (TNFR-IgG; 0.8-20 μg/mouse; i.v.; once) 当内毒素激发之前或之后不久给药时，可以预防或显著延迟内毒素诱导的小鼠致死率[2]。 Animal Model: |
| Name | Lenercept |
| CAS | 156679-34-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gater PR, et al. Inhibition of Sephadex-induced lung injury in the rat by Ro 45-2081, a tumor necrosis factor receptor fusion protein. Am J Respir Cell Mol Biol. 1996 May;14(5):454-60. [2]. Ashkenazi A, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10535-9. |